Warren D Taylor1, Brian D Boyd2, Damian Elson2, Patricia Andrews2, Kimberly Albert2, Jennifer Vega2, Paul A Newhouse3, Neil D Woodward2, Hakmook Kang4, Sepideh Shokouhi2. 1. The Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences (WDT, BDB, PA, KA, JV, PAN, NDW, HK, SS), Vanderbilt University Medical Center, Nashville, TN; Geriatric Research, Education, and Clinical Center (WDT, PAN), Veterans Affairs Tennessee Valley Health System, Nashville, TN. Electronic address: warren.d.taylor@vanderbilt.edu. 2. The Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences (WDT, BDB, PA, KA, JV, PAN, NDW, HK, SS), Vanderbilt University Medical Center, Nashville, TN. 3. The Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences (WDT, BDB, PA, KA, JV, PAN, NDW, HK, SS), Vanderbilt University Medical Center, Nashville, TN; Geriatric Research, Education, and Clinical Center (WDT, PAN), Veterans Affairs Tennessee Valley Health System, Nashville, TN. 4. Department of Biostatistics (HK), Vanderbilt University Medical Center, Nashville, TN.
Abstract
OBJECTIVE: Amyloid accumulation, the pathological hallmark of Alzheimer's disease, may predispose some older adults to depression and cognitive decline. Deposition of amyloid also occurs prior to the development of cognitive decline. It is unclear whether amyloid influences antidepressant outcomes in cognitively intact depressed elders. DESIGN: A pharmacoimaging trial utilizing florbetapir (18F) PET scanning followed by 2 sequential 8-week antidepressant medication trials. PARTICIPANTS: Twenty-seven depressed elders who were cognitively intact on screening. MEASUREMENTS AND INTERVENTIONS: After screening, diagnostic testing, assessment of depression severity and neuropsychological assessment, participants completed florbetapir (18F) PET scanning. They were then randomized to receive escitalopram or placebo for 8 weeks in a double-blinded two-to-one allocation rate. Individuals who did not respond to initial treatment transitioned to a second open-label trial of bupropion for another 8 weeks. RESULTS: Compared with 22 amyloid-negative participants, 5 amyloid-positive participants exhibited significantly less change in depression severity and a lower likelihood of remission. In the initial blinded trial, 4 of 5 amyloid-positive participants were nonremitters (80%), while only 18% (4 of 22) of amyloid-negative participants did not remit (p = 0.017; Fisher's Exact test). In separate models adjusting for key covariates, both positive amyloid status (t = 3.07, 21 df, p = 0.003) and higher cortical amyloid binding by standard uptake value ratio (t = 2.62, 21 df, p = 0.010) were associated with less improvement in depression severity. Similar findings were observed when examining change in depression status across both antidepressant trials. CONCLUSIONS: In this preliminary study, amyloid status predicted poor antidepressant response to sequential antidepressant treatment. Alternative treatment approaches may be needed for amyloid-positive depressed elders. Published by Elsevier Inc.
OBJECTIVE: Amyloid accumulation, the pathological hallmark of Alzheimer's disease, may predispose some older adults to depression and cognitive decline. Deposition of amyloid also occurs prior to the development of cognitive decline. It is unclear whether amyloid influences antidepressant outcomes in cognitively intact depressed elders. DESIGN: A pharmacoimaging trial utilizing florbetapir (18F) PET scanning followed by 2 sequential 8-week antidepressant medication trials. PARTICIPANTS: Twenty-seven depressed elders who were cognitively intact on screening. MEASUREMENTS AND INTERVENTIONS: After screening, diagnostic testing, assessment of depression severity and neuropsychological assessment, participants completed florbetapir (18F) PET scanning. They were then randomized to receive escitalopram or placebo for 8 weeks in a double-blinded two-to-one allocation rate. Individuals who did not respond to initial treatment transitioned to a second open-label trial of bupropion for another 8 weeks. RESULTS: Compared with 22 amyloid-negative participants, 5 amyloid-positive participants exhibited significantly less change in depression severity and a lower likelihood of remission. In the initial blinded trial, 4 of 5 amyloid-positive participants were nonremitters (80%), while only 18% (4 of 22) of amyloid-negative participants did not remit (p = 0.017; Fisher's Exact test). In separate models adjusting for key covariates, both positive amyloid status (t = 3.07, 21 df, p = 0.003) and higher cortical amyloid binding by standard uptake value ratio (t = 2.62, 21 df, p = 0.010) were associated with less improvement in depression severity. Similar findings were observed when examining change in depression status across both antidepressant trials. CONCLUSIONS: In this preliminary study, amyloid status predicted poor antidepressant response to sequential antidepressant treatment. Alternative treatment approaches may be needed for amyloid-positive depressed elders. Published by Elsevier Inc.
Authors: Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2010-02 Impact factor: 4.105
Authors: George S Alexopoulos; Matthew J Hoptman; Dora Kanellopoulos; Christopher F Murphy; Kelvin O Lim; Faith M Gunning Journal: J Affect Disord Date: 2012-03-15 Impact factor: 4.839
Authors: Karine Madsen; Bo J Hasselbalch; Kristian S Frederiksen; Mette E Haahr; Anders Gade; Ian Law; Julie C Price; Gitte M Knudsen; Lars V Kessing; Steen G Hasselbalch Journal: Neurobiol Aging Date: 2011-12-20 Impact factor: 4.673
Authors: Carmen Andreescu; Olusola Ajilore; Howard J Aizenstein; Kimberly Albert; Meryl A Butters; Bennett A Landman; Helmet T Karim; Robert Krafty; Warren D Taylor Journal: Am J Geriatr Psychiatry Date: 2019-08-07 Impact factor: 4.105
Authors: Robert S Wilson; Ana W Capuano; Patricia A Boyle; George M Hoganson; Loren P Hizel; Raj C Shah; Sukriti Nag; Julie A Schneider; Steven E Arnold; David A Bennett Journal: Neurology Date: 2014-07-30 Impact factor: 9.910
Authors: Kenia Kelly Fiaux do Nascimento; Kelly P Silva; Leandro F Malloy-Diniz; Meryl A Butters; Breno S Diniz Journal: J Psychiatr Res Date: 2015-07-26 Impact factor: 4.791
Authors: Jennifer R Gatchel; Jennifer S Rabin; Rachel F Buckley; Joseph J Locascio; Yakeel T Quiroz; Hyun-Sik Yang; Patrizia Vannini; Rebecca E Amariglio; Dorene M Rentz; Michael Properzi; Nancy J Donovan; Deborah Blacker; Keith A Johnson; Reisa A Sperling; Gad A Marshall Journal: JAMA Netw Open Date: 2019-08-02
Authors: Ryan Ahmed; Claire Ryan; Seth Christman; Damian Elson; Camilo Bermudez; Bennett A Landman; Sarah M Szymkowicz; Brian D Boyd; Hakmook Kang; Warren D Taylor Journal: Am J Geriatr Psychiatry Date: 2021-11-28 Impact factor: 7.996